La vocation d'OncoDiag est de mettre au point et de commercialiser de nouveaux tests non invasifs de suivi, de diagnostic et de dépistage ciblé de cancers.
OncoDiag, a simplified joint stock company with equity of 79,300 Euros, was established in 2013. The company is specialized in the development of innovative solutions for the early diagnosis, and monitoring of cancers with the bladder cancer and colorectal cancer as our priority. The company is based in Normandy into the Pépinière Scientifique located at 9 rue de Pacy, 27930 Miserey (Eure).
OncoDiag has developed and clinically validated a test named “Urotest”, a noninvasive urine test affording outstanding performances in the diagnosis and the surveillance of bladder cancer. These performances are similar to cystoscopy. The test is based on molecular approach combining genetic and epigenetic assays.
For colorectal cancer, we have pre-validated a new approach named “Colodiag”, a new noninvasive blood test, affording a diagnostic precision similar to colonoscopy, for the early detection of colorectal cancer . Colodiag is based on accurate quantification of protein/peptide biomarkers by targeted mass spectrometry, which is a low cost, easy to perform, reproducible and fast process.
These two products respond to totally unmet medical needs.
The company management consists of a highly qualified and experienced team with complementary expertise in clinical research, biotechnological development, strategic planning, finance, and business operations.